-
Mashup Score: 17
The origins of cancer vaccines date back to the 1800s. Since then, there have been significant efforts to generate vaccines against solid and hematologic malignancies using a variety of platforms. To date, these efforts have generally been met with minimal success. However, in the era of improved methods and technological advancements, supported by compelling preclinical and clinical data, a wave of renewed interest in the field offers the promise of discovering field-changing paradigms in the management of established and resected disease using cancer vaccines. These include novel approaches to personalized neoantigen vaccine development, as well as innovative immune-modulatory vaccines (IMVs) that facilitate activation of antiregulatory T cells to limit immunosuppression caused by regulatory immune cells. This article will introduce some of the limitations that have affected cancer vaccine development over the past several decades, followed by an introduction to the latest advancemen
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18Follow the 2024 ASCO Annual Meeting on Social Media - 2 day(s) ago
Social media provides a vibrant channel for connection and collaboration with the global oncology community during ASCO24. Follow along for live updates on key research and onsite happenings.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18Follow the 2024 ASCO Annual Meeting on Social Media - 2 day(s) ago
Social media provides a vibrant channel for connection and collaboration with the global oncology community during ASCO24. Follow along for live updates on key research and onsite happenings.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease - 3 day(s) ago
Combination chemotherapy with or without radiation has served as the primary therapeutic option for classic Hodgkin lymphoma (cHL), leading to durable remission in a majority of patients with early- and advanced-stage cHL. Patients with relapsed/refractory (RR) cHL could still be cured with salvage chemotherapy and autologous stem-cell transplantation. Brentuximab vedotin (BV) and the anti–PD-1–blocking antibodies, nivolumab and pembrolizumab, are highly effective treatments for cHL and have revolutionized the management of the disease. Recent studies incorporating BV and PD-1 blockade into salvage therapy for RR cHL and into frontline treatment regimens have changed the cHL treatment paradigm. The novel agents are also useful in the treatment of older patients who have poor outcomes with traditional therapy. This manuscript will review current strategies for approaching the management of previously untreated, RR, and challenging populations with cHL, including how to incorporate the n
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond - 3 day(s) ago
Low-grade gliomas present a formidable challenge in neuro-oncology because of the challenges imposed by the blood-brain barrier, predilection for the young adult population, and propensity for recurrence. In the past two decades, the systematic examination of genomic alterations in adults and children with primary brain tumors has uncovered profound new insights into the pathogenesis of these tumors, resulting in more accurate tumor classification and prognostication. It also identified several common recurrent genomic alterations that now define specific brain tumor subtypes and have provided a new opportunity for molecularly targeted therapeutic intervention. Adult-type diffuse low-grade gliomas are frequently associated with mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), resulting in production of 2-hydroxyglutarate, an oncometabolite important for tumorigenesis. Recent studies of IDH inhibitors have yielded promising results in patients at early stages of disease with prol
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15
Palliative care (PC) plays a critical role in managing the difficulties associated with genitourinary malignancies. Its primary aim is to improve the overall health of patients, provide support to both patients and their caregivers, and help individuals to navigate the complex decisions about treatment and end-of-life care. PC takes a holistic approach to patient care, recognizing that genitourinary malignancies affect multiple aspects of a person’s life. By addressing physical, emotional, social, and spiritual needs, PC aims to provide comprehensive support that is consistent with the patient’s values and preferences. The goal is to optimize comfort, minimize distress, and enhance the patient’s quality of life throughout the course of the illness. PC is not a one-off intervention, but an ongoing source of support. This article aims to provide a thorough overview of the critical elements involved in addressing the challenges posed by genitourinary cancers, emphasizing the importance of
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18Follow the 2024 ASCO Annual Meeting on Social Media - 3 day(s) ago
Social media provides a vibrant channel for connection and collaboration with the global oncology community during ASCO24. Follow along for live updates on key research and onsite happenings.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy - 8 day(s) ago
The treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (anti-PD1) with or without chemotherapy has led to an improvement in survival. Yet, despite this therapeutic advancement, only 15%-19% of patients remain alive at four years, highlighting the poor survival and unmet need for improved therapies for this patient population. Some of the key evolving novel therapeutics beyond anti-PD1 in R/M HNSCC have included therapeutic vaccine therapies, bispecific antibodies/fusion proteins and multitargeted kinase inhibitors, and antibody-drug conjugates (ADCs). Multiple concurrent investigations of novel therapeutics for patients with R/M HNSCC beyond anti-PD(L)1 inhibition are currently underway with some promising early results. Beyond immune checkpoint inhibition, novel immunotherapeutic strategies including therapeutic vaccines ranging from targeting human papillomavirus–specific epitopes to personalized neoantigen vaccine
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma - 15 day(s) ago
Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the potential value of multigene testing in early lung adenocarcinoma (LUAD).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma - 15 day(s) ago
Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the potential value of multigene testing in early lung adenocarcinoma (LUAD).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers | American Society of Clinical Oncology Educational Book https://t.co/xIg5aDld4c #ASCO24 @PBarataMD @hoperugo